Skip to Main Content

An official website of the United States government

Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals

About this Publication
Title
Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals
Pubmed ID
26921332 (View this publication on the PubMed website)
Digital Object Identifier
Publication
N/A
Authors
Jonathan N Hofmann 1, Brenda M Birmann 2, Lauren R Teras 3, Ruth M Pfeiffer 4, Ye Wang 5, Demetrius Albanes 4, Dalsu Baris 4, Graham A Colditz 6, Anneclaire J De Roos 7, Graham G Giles 8, H Dean Hosgood 9, Qing Lan 4, Ola Landgren 10, Linda M Liao 4, Nathaniel Rothman 4, Stephanie J Weinstein 4, Michael N Pollak 5, Marian L Neuhouser 11, Mark P Purdue 4
Affiliations
  • 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland. hofmannjn@mail.nih.gov.
  • 2Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • 3American Cancer Society, Atlanta, Georgia.
  • 4Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • 5Oncology Department, McGill University and Segal Cancer Centre, Jewish General Hospital, Montreal, Quebec, Canada.
  • 6Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. Department of Surgery and Alvin J. Siteman Cancer Center, Washington University School of Medicine, and Barnes Jewish Hospital, St. Louis, Missouri.
  • 7School of Public Health, Drexel University, Philadelphia, Pennsylvania.
  • 8Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • 9Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
  • 10Myeloma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
...show more
  • 11Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Abstract

The association between obesity and multiple myeloma risk may be partly attributed to reduced circulating levels of adiponectin in obese individuals. To prospectively evaluate multiple myeloma risk in relation to adiponectin levels overall and stratified by body mass index and other characteristics, we conducted a pooled investigation of pre-diagnosed peripheral blood samples from 624 multiple myeloma cases and 1,246 individually matched controls from seven cohorts participating in the Multiple Myeloma Cohort Consortium. Analysis of circulating analyte levels measured by ELISA revealed that higher total adiponectin levels were associated with reduced multiple myeloma risk overall [highest quartile vs. lowest: OR, 0.64; 95% confidence interval (CI) 0.47-0.85; Ptrend = 0.001]. This association was apparent among cases diagnosed six or more years after blood collection (OR, 0.60; 95% CI, 0.40-0.90; Ptrend = 0.004) and was similar in magnitude for men and women (OR, 0.59 and 0.66, respectively). Interestingly, we observed strong associations among subjects who were overweight (OR, 0.41; 95% CI, 0.26-0.65) or obese (OR, 0.41; 95% CI, 0.17-0.98) but not among those with normal weight (OR, 1.20; 95% CI, 0.73-2.00; overweight/obese vs. normal weight, Pinteraction = 0.04). Our findings provide the strongest epidemiologic evidence to date that adiponectin protects against multiple myeloma development, particularly among overweight and obese individuals, and offer a method for risk assessment in this susceptible population of heavier patients. Cancer Res; 76(7); 1935-41. ©2016 AACR.

Related CDAS Studies
Related CDAS Projects